The Medical Letter on Drugs and Therapeutics
Ocrelizumab (Ocrevus) for MS
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ocrelizumab (Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first anti-CD20 monoclonal antibody to be approved for treatment of MS and the first disease-modifying drug to be approved in the US for primary progressive MS.

STANDARD TREATMENT — Most patients with MS present with the relapsing-remitting form of the disease. About 10-15% have the primary progressive form, which is characterized by worsening neurological function from the time of symptom onset.1,2

Primary Progressive MS – Drugs used for treatment of primary progressive MS have included intravenous (IV) glucocorticoids, oral or subcutaneous (SC) methotrexate, IV or SC cladribine, IV immune globulin, and IV mitoxantrone. None of these drugs are approved ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ocrelizumab (Ocrevus) for MS
Article code: 1523b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian